← Back to Analyst Consensus 
ATYR Buy
aTYR PHARMA INC
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| May 20, 2026 | Freedom Broker | upgrade | Hold → Buy | — | 59% |
| Nov 7, 2025 | RBC Capital | maintain | Sector Perform → Sector Perform | $1 | 55% |
| Sep 16, 2025 | Wells Fargo | downgrade | Overweight → Equal-Weight | $1 | 54% |
| Sep 16, 2025 | RBC Capital | downgrade | Outperform → Sector Perform | $1.5 | 55% |
| Sep 15, 2025 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Sep 15, 2025 | Leerink Partners | downgrade | Outperform → Market Perform | $1 | 51% |
| Sep 15, 2025 | Jones Trading | downgrade | Buy → Hold | $0 | 50% |
| Sep 15, 2025 | Cantor Fitzgerald | downgrade | Overweight → Neutral | $0 | 50% |
| Sep 15, 2025 | LUCID CAPITAL MARKETS | downgrade | Buy → Neutral | $1 | 32% |
| Aug 22, 2025 | Jefferies | maintain | Buy → Buy | $17 | 52% |
| Jun 20, 2025 | Wells Fargo | maintain | Overweight → Overweight | $25 | 54% |
| Jun 4, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| May 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Mar 14, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Feb 18, 2025 | Leerink Partners | initiate | — → Outperform | $16 | 51% |
| Jan 6, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Dec 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Dec 3, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Oct 29, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Oct 4, 2024 | Wells Fargo | initiate | — → Overweight | $17 | 54% |
| Sep 5, 2024 | Jefferies | initiate | — → Buy | $9 | 52% |
| Aug 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Aug 14, 2024 | RBC Capital | reiterate | Outperform → Outperform | $16 | 55% |
| Aug 1, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Jul 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| May 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| May 3, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Mar 15, 2024 | RBC Capital | maintain | Outperform → Outperform | $16 | 55% |
| Mar 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Feb 21, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
Price Target Trend
Apr 26, 2026 Latest: $2.86 Oct 25, 2026
EPS Estimates
+1q $-0.09
Lo: $-0.16 Hi: $-0.06
7 analysts ▲5
+1y $-0.44
Lo: $-0.93 Hi: $-0.16
8 analysts ▲4
0y $-0.41
Lo: $-0.50 Hi: $-0.36
7 analysts ▲5
0q $-0.10
Lo: $-0.12 Hi: $-0.08
7 analysts ▲5
Cross-Platform Signals
No cross-platform signals in the last 90 days